EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis

Jacopo Mariotti iD, Chiara Pinton, Laura Giordano, Daniela Taurino, Barbara Sarina, Chiara De Philippis, Daniele Mannina iD, Cristina Tentori, Armando Santoro, Stefania Bramanti

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jacopo Mariotti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology/Hematology, IRCCS Humanitas Research Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Salvage Therapy, Hodgkin Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health's 'Ricerca Corrente', IRCCS Humanitas Research Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brentuximab VedotinSalvage TherapyHodgkin DiseaseHematopoietic Stem Cell TransplantationImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedRecurrenceTransplantation, HomologousAdolescentIncidenceAgedYoung AdultAllografts

Stichwörter der Autor:innen

GVHDHodgkins lymphomacytomegalovirustransplantation

Substanzen

Brentuximab VedotinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology/Hematology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Biostatistic Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Jacopo Mariotti, Daniele Mannina

Förderung

  • Italian Ministry of Health's 'Ricerca Corrente'
  • IRCCS Humanitas Research Hospital

Zitieren

APA

Mariotti, J., Pinton, C., Giordano, L., Taurino, D., Sarina, B., De Philippis, C., Mannina, D., Tentori, C., Santoro, A., & Bramanti, S. (2025). Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.70091

Vancouver

Mariotti J, Pinton C, Giordano L, Taurino D, Sarina B, De Philippis C, et al. Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis. British Journal of Haematology. 2025. doi:10.1111/bjh.70091

BibTeX
@article{Mariotti2025,
  author = {Mariotti, Jacopo and Pinton, Chiara and Giordano, Laura and Taurino, Daniela and Sarina, Barbara and De Philippis, Chiara and Mannina, Daniele and Tentori, Cristina and Santoro, Armando and Bramanti, Stefania},
  title = {Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70091}
}
Kostenlos starten →